High Free Cash Flow Stocks
PCRX is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
PACIRA BIOSCIENCES INC (PCRX) Stock Price & Overview
NASDAQ:PCRX • US6951271005
Current stock price
24.64 USD
-0.26 (-1.04%)
At close:
24.64 USD
0 (0%)
After Hours:
The current stock price of PCRX is 24.64 USD. Today PCRX is down by -1.04%. In the past month the price increased by 8.79%. In the past year, price decreased by -4.2%.
PCRX Key Statistics
52-Week Range18.8 - 27.64
Current PCRX stock price positioned within its 52-week range.
1-Month Range21.96 - 25.315
Current PCRX stock price positioned within its 1-month range.
- Market Cap
- 997.674M
- P/E
- 9.37
- Fwd P/E
- 9.12
- EPS (TTM)
- 2.63
- Dividend Yield
- N/A
PCRX Stock Performance
Today
-1.04%
1 Week
+3.75%
1 Month
+8.79%
3 Months
+19.21%
Longer-term
6 Months +13.34%
1 Year -4.20%
2 Years -6.13%
3 Years -45.62%
5 Years -61.00%
10 Years -54.46%
PCRX Stock Chart
PCRX Stock Screens
PCRX currently appears in the following ChartMill screener lists.
Low P/E Stocks
PCRX is currently part of our Low P/E Stocks screen, indicating it cheap while it also meets financial health criteria.
Value Stocks with Strong Balance Sheets
PCRX is currently part of our value stocks with Strong Balance Sheets screen, indicating it cheap while meeting strict financial health and debt criteria.
Graham Number Stocks
PCRX appears in our Graham Number Stocks screen. This means the stock is trading below its Graham Number, a classic value investing estimate based on earnings and book value, while also meeting basic quality and liquidity requirements.
PCRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PCRX. When comparing the yearly performance of all stocks, PCRX turns out to be only a medium performer in the overall market: it outperformed 52.43% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PCRX. While PCRX has a great health rating, its profitability is only average at the moment.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PCRX Earnings
On February 26, 2026 PCRX reported an EPS of 0.57 and a revenue of 196.87M. The company missed EPS expectations (-38.21% surprise) and missed revenue expectations (-3.7% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.57
Revenue Reported196.873M
EPS Surprise -38.21%
Revenue Surprise -3.70%
PCRX Forecast & Estimates
13 analysts have analysed PCRX and the average price target is 29.29 USD. This implies a price increase of 18.87% is expected in the next year compared to the current price of 24.64.
For the next year, analysts expect an EPS growth of 2.7% and a revenue growth 4.19% for PCRX
Analysts
Analysts76.92
Price Target29.29 (18.87%)
EPS Next Y2.7%
Revenue Next Year4.19%
PCRX Groups
Sector & Classification
PCRX Financial Highlights
Over the last trailing twelve months PCRX reported a non-GAAP Earnings per Share(EPS) of 2.63. The EPS decreased by -18.07% compared to the year before.
Income Statements
Revenue(TTM)726.41M
Net Income(TTM)7.03M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.97% | ||
| ROA | 0.56% | ||
| ROE | 1.01% | ||
| Debt/Equity | 0.54 |
Chartmill High Growth Momentum
EPS Q2Q%-37.36%
Sales Q2Q%5.14%
EPS 1Y (TTM)-18.07%
Revenue 1Y (TTM)-16.32%
PCRX Ownership
Ownership
Inst Owners119.39%
Shares40.49M
Float39.15M
Ins Owners2.16%
Short Float %20.59%
Short Ratio10.45
PCRX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.83 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.11 | 289.223B | ||
| PFE | PFIZER INC | 9.14 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 120.728B | ||
| ZTS | ZOETIS INC | 16.71 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.443B | ||
| VTRS | VIATRIS INC | 5.91 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.11 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PCRX
Company Profile
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 829 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Company Info
IPO: 2011-02-03
PACIRA BIOSCIENCES INC
2000 Sierra Point Parkway, Suite 900
Brisbane California CALIFORNIA 07054 US
CEO: David Stack
Employees: 827
Phone: 16502428052
PACIRA BIOSCIENCES INC / PCRX FAQ
What does PACIRA BIOSCIENCES INC do?
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 829 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Can you provide the latest stock price for PACIRA BIOSCIENCES INC?
The current stock price of PCRX is 24.64 USD. The price decreased by -1.04% in the last trading session.
What is the dividend status of PACIRA BIOSCIENCES INC?
PCRX does not pay a dividend.
How is the ChartMill rating for PACIRA BIOSCIENCES INC?
PCRX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in PACIRA BIOSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PCRX.
What is the employee count for PCRX stock?
PACIRA BIOSCIENCES INC (PCRX) currently has 827 employees.
What is the market capitalization of PCRX stock?
PACIRA BIOSCIENCES INC (PCRX) has a market capitalization of 997.67M USD. This makes PCRX a Small Cap stock.